Gene: BRD9
Official Full Name: bromodomain containing 9provided by HGNC
Gene Summary: Enables lysine-acetylated histone binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Located in nucleoplasm. Part of SWI/SNF complex. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO01319 | BRD9 Knockout cell line (HeLa) | Human | BRD9 | 1:3~1:6 | Negative | Online Inquiry |
KO09332 | BRD9 Knockout cell line (HCT 116) | Human | BRD9 | 1:2~1:4 | Negative | Online Inquiry |
KO09333 | BRD9 Knockout cell line (HEK293) | Human | BRD9 | 1:3~1:6 | Negative | Online Inquiry |
KO09334 | BRD9 Knockout cell line (A549) | Human | BRD9 | 1:3~1:4 | Negative | Online Inquiry |
BRD9 Gene Knockout Cell Lines are highly specialized cellular models engineered to lack the expression of the BRD9 gene, which encodes a critical component of the BAF (BRG1-associated factor) chromatin-remodeling complex. This product serves as a valuable tool for understanding the functional implications of BRD9 in cellular processes such as gene expression regulation, differentiation, and development. The knockout of BRD9 facilitates the examination of its role in chromatin dynamics and is particularly pertinent to studying various cancer types where BAF complexes are often mutated or dysregulated.
The primary mechanism by which BRD9 Gene Knockout Cell Lines operate is through the complete abrogation of BRD9 protein production. This results in the disruption of BAF complex-mediated chromatin remodeling, subsequently affecting the transcriptional landscape of the cell. Researchers can utilize this model to elucidate the gene's involvement in oncogenic pathways, potentially identifying novel therapeutic targets for drug development.
The scientific importance of these knockout cell lines extends into both basic and applied research contexts. They offer an innovative platform for investigating gene function, dissecting molecular pathways, and testing small molecule inhibitors that target BRD proteins or associated pathways. In clinical research, the applicability is evident in cancer studies, where BRD9’s role is under investigation for its therapeutic potential.
What sets our BRD9 Gene Knockout Cell Lines apart from alternative models is the precision and reproducibility achieved through rigorous genetic engineering techniques. Each line is validated for the complete knockout of BRD9, ensuring reliability in experimental outcomes. Additionally, our product is compatible with a variety of downstream applications, including CRISPR-mediated gene editing, drug response screening, and metabolic profiling.
For researchers and clinicians, the ability to work with these knockout cell lines translates into actionable insights that pave the way for innovative treatments and a deeper understanding of chromatin biology. Our extensive expertise in cellular models and commitment to scientific integrity ensures that our products meet the highest standards of quality and reliability, empowering researchers in their quest for breakthroughs in biology and medicine.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.